Two exact date revisions reported by the sponsors
Both earlier and revised targets are explicitly stated in the linked primary document. These retrospective records do not imply this pilot was monitoring the application when the earlier date was assigned.
Two selected retrospective source-confirmed revisions. Not a complete historical change log.
2026-11-14
| Relutrigine / SCN2A and SCN8A developmental and epileptic encephalopathies | 2026-09-27 | 2026-12-27 | November 9 10-Q retrospectively states the earlier target and the June 2026 extension. | Verify both dates |
| Mitapivat / Sickle cell disease | 2026-11-01 | 2027-02-01 | November 5 release explicitly states both dates and a three-month major-amendment extension. | Verify both dates |
No matching records. Try a broader search.
Changes documented in this selected cohort
The source notes below explain application scope and disclosed revisions. They are context notes, not a complete event-by-event history.
2026-11-14
| MOLBREEVI (molgramostim inhalation solution) | Sponsor describes a three-month extension following a major amendment. No earlier exact goal date inferred. | Verify |
| D-PLEX100 | Source describes labeling discussions; this is not an approval or launch date. | Verify |
| Relacorilant | Specific to Cushing’s syndrome; do not confuse with other relacorilant indications. | Verify |
| Imlifidase | U.S. milestone; the EU authorization is a separate regulatory event. | Verify |
| Relutrigine | Updated goal date after a major amendment; not a forecast of approval. | Verify |
| Ulixacaltamide HCl | Separate application and indication from relutrigine. | Verify |
| Mitapivat | Supplemental application for sickle cell disease; other mitapivat indications do not determine this status. | Verify |
No matching records. Try a broader search.
A revision is a new observation
Savara describes a three-month extension in its quarterly filing; Praxis describes an updated relutrigine review target in its disclosures. These are reasons to retain the date history. They do not justify estimating an earlier exact date from arithmetic.
Record an old target only if a dated primary source explicitly states it. For a new date, add the announcement date, old source, new source and the sponsor’s stated reason. Preserve uncertainty when the reason is not given.
After the goal date
Do not infer a decision from the passage of time. Check current sponsor announcements, any SEC-filed release, and FDA material. If no action can be confirmed, label the row “goal date passed — outcome needs review” and retain the last supported target.
When a decision is confirmed, record the action and its own source separately from the historical goal date. That makes later timing analysis possible without erasing the original expectation.
Source notes
- Savara — MOLBREEVI (molgramostim inhalation solution) ↗
Sponsor-reported goal date and indication; source dated 2026-11-09
- PolyPid — D-PLEX100 ↗
Sponsor-reported goal date and indication; source dated 2026-11-11
- Corcept Therapeutics — Relacorilant ↗
Sponsor-reported goal date and indication; source dated 2026-11-03
- Hansa Biopharma — Imlifidase ↗
Sponsor-reported goal date and indication; source dated 2026-11-11
- Praxis Precision Medicines — Relutrigine ↗
Sponsor-reported goal date and indication; source dated 2026-11-09
- Praxis Precision Medicines — Ulixacaltamide HCl ↗
Sponsor-reported goal date and indication; source dated 2026-11-09
- Agios Pharmaceuticals — Mitapivat ↗
Sponsor-reported goal date and indication; source dated 2026-11-05
The Synoptic workflow
Explore the Synoptic workflow
See how this topic connects to source-linked streams, APIs and research tools.
Explore the Synoptic workflow